Prescription practice for LH-RH analogs and androgen receptor antagonists in the treatment of advanced prostate cancer in Germany (1993-2003)

Urologia Internationalis

Volumn 77, Issue 4, 2006, Pages 311-316

  Rohde, Volker ^a   Diemer, Thorsten ^a   Hauck, Ekkehard ^a   Bestmann, Beate ^b   Miller, Jörg ^a   Schröder, Helmut ^c   Weidner, Wolfgang ^a   Katalinic, Alexander ^d  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c German Drug Index AOK Research Institute (WidO)   (Germany)

^d UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Age standardized incidence rate, prostate cancer; Androgen receptor antagonists; Daily doses, LH RH analogs androgen receptor antagonists; LH RH analogs; Prescription practice, LH RH analogs androgen receptor antagonists; Prostate cancer

Indexed keywords

ANTIANDROGEN; GONADORELIN DERIVATIVE;

ADVANCED CANCER; ARTICLE; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER MORTALITY; GERMANY; HUMAN; MALE; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE CANCER;

AGED; ANDROGEN ANTAGONISTS; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; FOLLOW-UP STUDIES; GERMANY; GONADOTROPIN-RELEASING HORMONE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PRESCRIPTIONS, DRUG; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RETROSPECTIVE STUDIES;

EID: 33751515382     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000096334     Document Type: Article

References (14)

1. Arbeitsgemeinschaft bevölkerungsbezogener Krebsregister in Deutschland: Krebs in Deutschland. Saarbrücken 2004.
2. National Cancer Institute - SEER (2004) http://seer.cancer.gov/faststats/ html/inc_prost.html.
3. Dennis LK, Resnick MI: Analysis of recent trends in prostate cancer incidence and mortality. Prostate 2000;42:247-252.
4. McDavid K, Lee J, Fulton JP, Tonita J, Thompson TD: Prostate cancer incidence and mortality rates and trends in the United States and Canada. Public Health Rep 2004;119:174-186.
5. Seidenfeld J, Samson DJ, Hasselblad V, Aronson N, Albertsen PC, Bennett CL, Wilt TJ: Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000;132:566-577.
6. Nink K, Schröder H: Ökonomische Aspekte des deutschen Arzneimittelmarktes; in Schwabe U, Paffrath D (eds): Arzneiverordnungs-Report 2004. Berlin, Springer, 2004.
7. Nink K, Schröder H: Arzneiverordnungen nach Alter und Geschlecht; in Schwabe U, Paffrath D (eds): Arzneiverordnungs-Report 2004. Berlin, Springer, 2004.
8. Seidenfeld J, Samson DJ, Aronson N, Albertson PC, Bayoumi AM, Bennett C, Brown A, Garber A, Gere M, Hasselblad V, Wilt T, Ziegler K: Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. Evidence Rep Technol Assess Summ, May 1999.
9. www.destatis.de
10. Bayoumi AM, Brown AD, Garber AM: Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. J Natl Cancer Inst 2000;92:1731-1739.
11. Rohde V, Wellmann A, Fogt F, Weidner W, Katalinic A: Economical data and advanced prostate carcinoma: do we need new guidelines for decision making? Oncol Rep 2002;9:1185-1188.
12. Aus G, Abbou CC, Pacik D, Schmid HP, van Poppel H, Wolff JM, Zattoni F; EAU Working Group on Oncological Urology: EAU guidelines on prostate cancer. Eur Urol 2001;40:97-101.
13. Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H: Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol 2000;164:101-105.
14. www.wido.de.